

Publikationsliste 2012

Originalpublikationen

1. Aalen OO, Roysland K, Gran JM, Ledergerber B. Causality, mediation and time: a dynamic viewpoint. *J R Stat Soc Ser A Stat Soc.* 2012; 175(4): 831-61.
2. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, Trkola A. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. *PLoS Pathog.* 2012; 8(4): e1002634.
3. Achermann Y, Eigenmann K, Ledergerber B, Derksen L, Rafeiner P, Clauss M, Nuesch R, Zellweger C, Vogt M, Zimmerli W. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched casecontrol study. *Infection.* 2012. [Epub ahead of print]
4. Achermann Y, Sahin F, Schwyzer H, Kolling C, Wust J, Vogt M. Characteristics and outcome of 16 periprosthetic shoulder joint infections. *Infection.* 2012. [Epub ahead of print]
5. Althaus CF, Vongrad V, Niederost B, Joos B, Di Giallonardo F, Rieder P, Pavlovic J, Trkola A, Gunthard HF, Metzner KJ, Fischer M. Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. *Retrovirology.* 2012; 9:27.
6. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Gunthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. *Antimicrob Agents Chemother.* 2012; 56(6): 2959-66.
7. Arenas-Pinto A, Weller I, Ekong R, Grant A, Karstaedt A, Reiss P, Telisinghe L, Weber R, Bolhaar M, Bradman N, Ingram C. Common inherited mitochondrial DNA mutations and nucleoside reverse transcriptase inhibitor-induced severe hyperlactataemia in HIV-infected adults: an exploratory study. *Antivir Ther.* 2012; 17(2): 275-82.
8. Bansal V, Altermatt S, Nadal D, Berger C. Lack of benefit of preoperative antimicrobial prophylaxis in children with acute appendicitis: a prospective cohort study. *Infection.* 2012; 40(6): 635-41.
9. Birrenbach T, Bertschy S, Aebersold F, Mueller NJ, Achermann Y, Muehlethaler K, Zimmerli S. Emergence of *Blastoschizomyces capitatus* yeast infections, Central Europe. *Emerg Infect Dis.* 2012; 18(1): 98-101.
10. Boillat-Blanco N, Darling KE, Taffe P, Osih R, Strahm C, Adami M, Elzi L, Daou S, Fehr J, Wandeler G, Cavassini M. Impact of recommendation updates in wellcontrolled patients on non-recommended antiretroviral therapies: the Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr.* 2012. [Epub ahead of print]
11. Bonetti NR, Namdar M, Guenthard HF, Gruner C, Greutmann M, Steffel J, Hürlimann D, Ruef C, Tanner FC, Jenni R, Biaggi P. Early versus late initial

echocardiographic assessment in infective endocarditis: similar findings and no difference in clinical outcome. *Cardiovasc Medicine*. 2012; 15(11): 317-24.

12. Braun J, Held L, Ledergerber B. Predictive cross-validation for the choice of linear mixed-effects models with application to data from the Swiss HIV Cohort Study. *Biometrics*. 2012; 68(1): 53-61.
13. Bucher HC, Richter W, Glass TR, Magenta L, Wang Q, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer H, Battegay M, Bernasconi E. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr*. 2012; 60(2): 135-42.
14. Castagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczek D, Mocroft A, Dorrucchi M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fatkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, Garcia F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Costagliola D, Lodwick R, Phillips A. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. *Lancet Infect Dis*. 2012; 12(2): 119-27.
15. Clifford GM, Lise M, Franceschi S, Egger M, Bouchardy C, Korol D, Levi F, Ess S, Jundt G, Wandeler G, Fehr J, Schmid P, Battegay M, Bernasconi E, Cavassini M, Calmy A, Keiser O, Schoni-Affolter F. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. *Br J Cancer*. 2012; 106(3):447-52.
16. Coleman BL, Kuster SP, Gubbay J, Scheifele D, Li Y, Low D, Crowcroft N, Mazzulli T, Shi L, Halperin SA, Law B, McGeer A. Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. *Eur J Clin Microbiol Infect Dis*. 2012; 31(4): 591-7.
17. Colombo C, Senn G, Burgel A, Ruef C. Clearance of an epidemic clone of methicillin-resistant *Staphylococcus aureus* in a drug-use network: a follow-up study in Switzerland. *Scand J Infect Dis*. 2012; 44(9): 650-5.
18. Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. *HIV Med*. 2012; 13(1): 62-72.
19. Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Gunthard HF. Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. *J Acquir Immune Defic Syndr*. 2012. [Epub ahead of print]
20. Dobrick, Nadine; Müller, Nicolas; Franzen, Daniel Legionärskrankheit (Legionellen- Pneumonie) *Praxis* 2012;101(23):1459-1467.

21. Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, Gutmann C, Cusini A, Gunthard HF, Cavassini M, Vernazza PL. Marked Increase of the Astrocytic Marker S100B in the Cerebrospinal Fluid of HIV-infected Patients on LPV/r-Monotherapy. *AIDS*. 2012. [Epub ahead of print]
22. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. *PLoS One*. 2012; 7(9): e44454.
23. Elzi L, Erb S, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. *Arch Intern Med*. 2012. [Epub ahead of print]
24. Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, Pfyffer GE, Borrell S, Dubuis O, Bruderer T, Siegrist HH, Furrer H, Calmy A, Fehr J, Stalder JM, Ninet B, Bottger EC, Gagneux S. Effect of mutation and genetic background on drug resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2012; 56(6): 3047-53.
25. Fenner L, Gagneux S, Helbling P, Battegay M, Rieder HL, Pfyffer GE, Zwahlen M, Furrer H, Siegrist HH, Fehr J, Dolina M, Calmy A, Stucki D, Jaton K, Janssens JP, Stalder JM, Bodmer T, Ninet B, Bottger EC, Egger M. *Mycobacterium tuberculosis* transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. *J Clin Microbiol*. 2012; 50(2): 388-95.
26. Fenner L, Gagneux S, Janssens JP, Fehr J, Cavassini M, Hoffmann M, Bernasconi E, Schrenzel J, Bodmer T, Bottger EC, Helbling P, Egger M. Tuberculosis in HIVnegative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes. *PLoS One*. 2012; 7(3): e34186.
27. Fröhlich Knaute DF, Graf N, Lautenschlager S, Weber R, Bosshard PP. Serological Response to Treatment of Syphilis According to Disease Stage and HIV Status. *Clin Infect Dis*. 2012; 55(12): 1615-22.
28. Gasser O, Brander C, Wolbers M, Brown N, Rauch A, Gunthard H, Battegay M, Hess C. Expansion of interferon-gamma-secreting HIV-specific T cells during successful antiretroviral therapy. *HIV Med*. 2012. [Epub ahead of print]
29. Glass TR, Rotger M, Telenti A, Decosterd L, Csajka C, Bucher HC, Gunthard HF, Rickenbach M, Nicca D, Hirschel B, Bernasconi E, Wandeler G, Battegay M, Marzolini C. Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. *PLoS One*. 2012; 7(1): e29186.
30. Greiner M, Cusini A, Ruesch M, Schiesser M, Ledergerber B, Fehr T, Mueller NJ. A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. *Infection*. 2012; 40 (6): 669-675.

31. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Gunthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. *PLoS Pathog.* 2012; 8(3): e1002529.
32. Herbeck JT, Muller V, Maust BS, Ledergerber B, Torti C, Di Giambenedetto S, Gras L, Gunthard HF, Jacobson LP, Mullins JI, Gottlieb GS. Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. *AIDS.* 2012; 26(2): 193-205.
33. Huber M, Ledergerber B, Sauter R, Young J, Fehr J, Cusini A, Battegay M, Calmy A, Orasch C, Nicca D, Bernasconi E, Jaccard R, Held L, Weber R. Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. *HIV Med.* 2012; 13(7): 387-97.
34. Hunziker T, Berger C, Staubli G, Tschopp A, Weber R, Nadal D, Hatz C, Schlagenhauf P. Profile of travel-associated illness in children, Zurich, Switzerland. *J Travel Med.* 2012; 19(3): 158-62.
35. Keiser O, Spycher B, Rauch A, Calmy A, Cavassini M, Glass TR, Nicca D, Ledergerber B, Egger M. Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis. *AIDS Behav.* 2012; 16(2): 245-55.
36. Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *Clin Infect Dis.* 2012. [Epub ahead of print]
37. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. *AIDS.* 2012; 26(3):315-23.
38. Latshang TD, Nussbaumer-Ochsner Y, Henn RM, Ulrich S, Lo Cascio CM, Ledergerber B, Kohler M, Bloch KE. Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial. *JAMA.* 2012; 308(22): 2390-8.
39. Ledergerber B, Costagliola D, Lodwick R, Torti C, van Sighem A, Podzamczar D, Mocroft A, Dorrucchi M, Masquelier B, Günthard HF, de Luca A, Michalik C, De Wit S, Obel N, Fätkenheuer G, Chrysos G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Grarup J, Chêne G, Phillips A. Predictors of CD4 cell counts of

- HIV-1 – infected persons after virologic failure to all three original antiretroviral drug classes. *J Infect Dis.* 2012 Dec 7. [Epub ahead of print]
40. Leventhal GE, Kouyos R, Stadler T, Wyl V, Yerly S, Boni J, Cellerai C, Klimkait T, Gunthard HF, Bonhoeffer S. Inferring epidemic contact structure from phylogenetic trees. *PLoS Comput Biol.* 2012; 8(3): e1002413.
 41. Li JZ, Paredes R, Ribaud HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure. *J Infect Dis.* 2012. [Epub ahead of print]
 42. Longtin Y, Farquet N, Gayet-Ageron A, Sax H, Pittet D. Caregivers' perceptions of patients as reminders to improve hand hygiene. *Arch Intern Med.* 2012 Oct 22;172(19):1516-7.
 43. Lubomirov R, Arab-Alameddine M, Rotger M, Fayet-Mello A, Martinez R, Guidi M, di Iulio J, Cavassini M, Gunthard HF, Furrer H, Marzolini C, Bernasconi E, Calmy A, Buclin T, Decosterd LA, Csajka C, Telenti A. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. *Pharmacogenet Genomics.* 2012. [Epub ahead of print]
 44. Maurer FP, Keller PM, Beuret C, Joha C, Achermann Y, Gubler J, Bircher D, Karrer U, Fehr J, Zimmerli L, Bloemberg GV. Close Geographic Association of Human Neoehrlichiosis and Tick Populations Carrying "Candidatus Neoehrlichia mikurensis" in Eastern Switzerland. [Epub ahead of print]
 45. May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiebaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. *Int J Epidemiol.* 2012; 41(6): 1807-1820.
 46. Mekker A, Tchang VS, Haeberli L, Oxenius A, Trkola A, Karrer U. Immune senescence: relative contributions of age and cytomegalovirus infection. *PLoS Pathog.* 2012; 8(8): e1002850.
 47. Mocroft A, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Kirk O, Lundgren J. CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. *J Int AIDS Soc.* 2012; 15(6): 18191.
 48. Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill MJ, Harris RJ, Reiss P, Justice A, Kirk O, Saag M, Smith CJ, Weber R, Rockstroh J, Khaykin P, Sterne J. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. *HIV Med.* 2012; 13(2): 89-97.
 49. Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczek D, Mocroft A, Ledergerber B, Dorrucchi M, Cozzi-Lepri A, Jansen K, Masquelier B,

- Garcia F, De Wit S, Stephan C, Obel N, Fatkenhaeuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. *J Acquir Immune Defic Syndr.* 2012; 59(3): 294-9.
50. Nemeth J, Ledergerber B, Preiswerk B, Nobile A, Karrer S, Ruef C, Kuster SP. Multidrug-resistant bacteria in travellers hospitalized abroad: prevalence, characteristics, and influence on clinical outcome. *J Hosp Infect.* 2012; 82(4): 254-259.
 51. Nemeth J, Rumetshofer R, Winkler HM, Burghuber OC, Muller C, Winkler S. Active tuberculosis is characterized by an antigen specific and strictly localized expansion of effector T cells at the site of infection. *Eur J Immunol.* 2012; 42(11): 2844-50.
 52. Nemeth J, Winkler HM, Zwick RH, Muller C, Rumetshofer R, Boeck L, Burghuber OC, Winkler S. Peripheral T cell cytokine responses for diagnosis of active tuberculosis. *PLoS One.* 2012; 7(4): e35290.
 53. Nischang M, Suttmuller R, Gers-Huber G, Audige A, Li D, Rochat MA, Baenziger S, Hofer U, Schlaepfer E, Regenass S, Amssoms K, Stoops B, Van Cauwenberge A, Boden D, Kraus G, Speck RF. Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1. *PLoS One.* 2012; 7(6): e38853.
 54. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Moller N, Lundgren JD, Law MG. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti- HIV Drugs (D:A:D) study. *J Int AIDS Soc.* 2012; 15(2): 17426.
 55. Petrusch U, Frauenfelder T, Mueller NJ, Arn K, Stussi G, Schanz U. Optimised radiological diagnosis of hepatic fungal infection during the treatment of leukemia. *Mycoses.* 2012; 55(5): 447-53.
 56. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Gunthard HF, Wong JK. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. *Proc Natl Acad Sci U S A.* 2012; 109(8): 3035-40.
 57. Prabhakaran S, Boehm A, Metzner KJ, Roth V. Recovering Networks from Distance Data. *Journal of Machine Learning Research.* 2012; 25: 349-64.
 58. Preiswerk B, Rudiger A, Fehr J, Corti N. Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. *Infection.* 2012. [Epub ahead of print]
 59. Sassi M, Ripamonti C, Mueller NJ, Yazaki H, Kutty G, Ma L, Huber C, Gogineni E, Oka S, Goto N, Fehr T, Gianella S, Konrad R, Sing A, Kovacs JA. Outbreaks of *Pneumocystis pneumonia* in 2 renal transplant centers linked to a single

strain of Pneumocystis: implications for transmission and virulence. *Clin Infect Dis.* 2012;54(10): 1437-44.

60. Savaria F, Zbinden R, Wust J, Burnens A, Ledergerber B, Weber R, Kovari H. [Antimicrobial resistance among *E. coli* in urinary specimens: prevalence data from three laboratories in Zurich between 1985 and 2010]. *Praxis (Bern 1994).* 2012;101(9): 573-9.
61. Scherrer AU, Boni J, Yerly S, Klimkait T, Aubert V, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Ledergerber B, Gunthard HF. Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. *PLoS One.* 2012; 7(11): e50307.
62. Scherrer AU, Ledergerber B, von Wyl V, Boni J, Yerly S, Klimkait T, Cellera C, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Gunthard HF. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. *PLoS One.* 2012; 7(6): e37983.
63. Scherrer AU, von Wyl V, Gotte M, Klimkait T, Cellera C, Yerly S, Boni J, Held L, Ledergerber B, Gunthard HF. Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M. *J Acquir Immune Defic Syndr.* 2012; 59(2): 105-12.
64. Schupbach J, Bisset LR, Gebhardt MD, Regenass S, Burgisser P, Gorgievski M, Klimkait T, Andreatti C, Martinetti G, Niederhauser C, Yerly S, Pfister S, Schultze D, Brandenberger M, Schoni-Affolter F, Scherrer AU, Gunthard HF. Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. *BMC Infect Dis.* 2012; 12: 88.
65. Seidl K, Zinkernagel AS. The MTT assay is a rapid and reliable quantitative method to assess *Staphylococcus aureus* induced endothelial cell damage. *J Microbiol Methods.* 2012. [Epub ahead of print]
66. Simmons R, Sharp C, McClure CP, Rohrbach J, Kovari H, Frangou E, Simmonds P, Irving W, Rauch A, Bowness P, Klenerman P. Parvovirus 4 infection and clinical outcome in high-risk populations. *J Infect Dis.* 2012; 205(12): 1816-20.
67. Spormann C, Achermann Y, Simmen BR, Schwyzer HK, Vogt M, Goldhahn J, Kolling C. Treatment strategies for periprosthetic infections after primary elbow arthroplasty. *J Shoulder Elbow Surg.* 2011; 21(8): 992-1000.
68. Stadler T, Kouyos R, von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Joos B, Rieder P, Xie D, Gunthard HF, Drummond AJ, Bonhoeffer S. Estimating the basic reproductive number from viral sequence data. *Mol Biol Evol.* 2012; 29(1): 347-57.
69. Staehelin C, Keiser O, Calmy A, Weber R, Elzi L, Cavassini M, Schmid P, Bernasconi E, Furrer H. Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr.* 2012; 59(1): 79-85.

70. Stern M, Czaja K, Rauch A, Rickenbach M, Gunthard HF, Battegay M, Fellay J, Hirschel B, Hess C. HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption. *HIV Med.* 2012; 13(10): 589-95.
71. Stiasny K, Aberle JH, Chmelik V, Karrer U, Holzmann H, Heinz FX. Quantitative determination of IgM antibodies reduces the pitfalls in the serodiagnosis of tick-borne encephalitis. *J Clin Virol.* 2012; 54(2): 115-20.
72. Taylor N, Grabmeier-Pfistershammer K, Oberkofler H, Egle A, Rieger A, Ledergerber B. Upgraded Cobas TaqMan version 2: hidden consequences at cohort level. *J Int AIDS Soc.* 2012; 15(6): 18207.
73. Thierfelder C, Keller PM, Kocher C, Gaudenz R, Hombach M, Bloemberg GV, Ruef C. Vancomycin-resistant *Enterococcus*. *Swiss Med Wkly.* 2012; 142: 0.
74. Thierfelder C, Weber R, Elzi L, Furrer H, Cavassini M, Calmy A, Bernasconi E, Gutmann C, Ledergerber B. Participation, characteristics and retention rates of HIVpositive immigrants in the Swiss HIV Cohort Study. *HIV Med.* 2012; 13(2): 118-26.
75. Uchiyama S, Andreoni F, Schuepbach RA, Nizet V, Zinkernagel AS. DNase Sda1 allows invasive M1T1 Group A *Streptococcus* to prevent TLR9-dependent recognition. *PLoS Pathog.* 2012; 8(6): e1002736.
76. von Wyl V, Yerly S, Boni J, Shah C, Cellera C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Gunthard HF. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. *Clin Infect Dis.* 2012; 54(1): 131-40.
77. Vrouenraets SM, Wit FW, Garcia EF, Huber M, Brinkman K, Moyle G, Domingo P, Tarr PE, Podzamczar D, Ristola M, Gatell JM, Livrozet JM, Furrer H, Reiss P; PREPARE Study Group. Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. *HIV Clin Trials.* 2012 Mar-Apr;13(2):103-10.
78. Wandeler G, Gsponer T, Bregenzer A, Gunthard HF, Clerc O, Calmy A, Stockle M, Bernasconi E, Furrer H, Rauch A. Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. *Clin Infect Dis.* 2012; 55(10): 1408-16.
79. Wang Q, Young J, Bernasconi E, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer H, Stoecke M, Bucher HC, Fux CA. The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: The Swiss HIV Cohort Study. *Antivir Ther.* 2012. [Epub ahead of print]
80. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, Cavassini M, Calmy A, Bernasconi E, Schmid P, Flepp M, Kowalska J, Ledergerber B. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. *HIV Med.* 2012. [Epub ahead of print]

81. Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, D'Arminio Monforte A, Law M, Phillips A, Ryom L, Dabis F, Weber R, Sabin C, Lundgren JD. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. *J Infect Dis.* 2012; 205(4): 535-9.
82. Young J, Schafer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. *AIDS.* 2012; 26(5):567-75.
83. Zbinden A, Mueller NJ, Tarr PE, Eich G, Schulthess B, Bahlmann AS, Keller PM, Bloemberg GV. *Streptococcus tigurinus*, a novel member of the *Streptococcus mitis* group, causes invasive infections. *J Clin Microbiol.* 2012; 50(9): 2969-73.
84. Zbinden A, Mueller NJ, Tarr PE, Sproer C, Keller PM, Bloemberg GV. *Streptococcus tigurinus* sp. nov., isolated from blood of patients with endocarditis, meningitis and spondylodiscitis. *Int J Syst Evol Microbiol.* 2012; 62(Pt 12): 2941-5.
85. Zinkernagel AS, Hruz P, Uchiyama S, von Kockritz-Blickwede M, Schuepbach RA, Hayashi T, Carson DA, Nizet V. Importance of Toll-like receptor 9 in host defense against M1T1 group A *Streptococcus* infections. *J Innate Immun.* 2012; 4(2): 213-8.
86. Zuercher E, Buttica C, Wyniger J, Martinez R, Battegay M, Boffi El Amari E, Dang T, Egger JF, Fehr J, Mueller-Garamvogyi E, Parini A, Schaefer SC, Schoeni-Affolter F, Thurnheer C, Tinguely M, Telenti A, Rothenberger S. Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Kappab activation. *PLoS One.* 2012; 7(2): e32168.

Case Reports

1. Achermann Y, Frauenfelder T, Obrist S, Zaugg K, Corti N, Gunthard HF. A rare but severe pulmonary side effect of cetuximab in two patients. *BMJ Case Rep.* 2012; [Epub ahead of print]
2. Braun D, Hasse B, Stricker J, Fehr J. Prosthetic valve endocarditis caused by *Propionibacterium* species successfully treated with co-administered rifampicin: report of two cases. *BMJ Case Rep.* 2012. [Epub ahead of print]
3. Glutz von Blotzheim L, Muller NJ, Huber LC, Degen T. [A 76-year-old female patient with deep venous thrombosis and cervical lymphadenopathy]. *Internist (Berl).* 2012; 53(6): 756-9.
4. Hohlfeld SK, Gunthard HF, Zeitz J, Locher P, Bachli E. Progressive multi-focal leukoencephalopathy as a rare lethal complication in untreated sarcoidosis. *BMJ Case Rep.* 2012. [Epub ahead of print]
5. Hugelshofer M, Achermann Y, Kovari H, Dent W, Hombach M, Bloemberg G. Meningoencephalitis with subdural empyema caused by toxigenic *Clostridium perfringens* type A. *J Clin Microbiol.* 2012; 50(10): 3409-11.

6. Kocher C, Segerer S, Schleich A, Caduff R, Wyler LG, Muller V, Beck B, Blum J, Kamarachev J, Mueller NJ. Skin lesions, malaise, and heart failure in a renal transplant recipient. *Transpl Infect Dis.* 2012; 14(4): 391-7.
7. Krones T, Rüegg CA, Guenthard HF, Rid A, Wild V. Heimlicher Transfer von HIVMedikamenten nach Afrika. *Ethik in der Medizin.* 2012; 24(1): 57-61. 8. Lederer H, Achermann Y, Tinguely M, Stenner F, Fehr J. Multicentric Castleman's disease as a cause for unclear febrile episodes in a 55-year-old HIV-infected man. *Infection.* 2012; 40(2): 203-5.
9. Stenzinger A, Nemeth J, Klauschen F, Schewe C, Ladhoff AM, Muckenhuber A, Schurmann M, Schurmann D, Weichert W. Visceral leishmaniasis in a patient with AIDS: early pathological diagnosis using conventional histology, PCR and electron microscopy is the key for adequate treatment. *Virchows Arch.* 2012; 460(3): 357-60.
10. Zbinden A, Imhof A, Wilhelm MJ, Ruschitzka F, Wild P, Bloemberg GV, Mueller NJ. Fatal outcome after heart transplantation caused by *Aspergillus lentulus*. *Transpl Infect Dis.* 2012; 14(5): E60-3.

Übersichtsartikel / Reviews

1. Beerenwinkel N, Gunthard HF, Roth V, Metzner KJ. Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. *Front Microbiol.* 2012; 3: 329.
2. Berger C, Boggian K, Cusini A, van Delden C, Garzoni C, Hirsch HH, Khanna N, Koller M, Manuel O, Meylan P, Nadal D, Weisser M, Mueller NJ. Relevance of cohort studies for the study of transplant infectious diseases. *Curr Opin Organ Transplant.* 2012;17(6): 581-5.
3. Nashan B, Gaston R, Emery V, Saemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. *Transplantation.* 2012; 93(11): 1075-85.
4. Nischang M, Gers-Huber G, Audige A, Akkina R, Speck RF. Modeling HIV infection and therapies in humanized mice. *Swiss Med Wkly.* 2012; 142: 13618.
5. Sax H. Seeing the System Inside-Out. *Reflections: The SoL Journal,* 2012;12(3):12-18.
6. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. *JAMA.* 2012; 308(4): 387-402.

Buchkapitel

1. Müller, N J; Fishman, J A. Infections in the liver transplant recipient. In: Clavien, P A; Trotter, J F; Müllhaupt, B. Medical care of the liver transplant patient. Chichester, UK, 2012: 380-388.
2. Weber R, Fontana A. Status febrilis. In: E Battegay (ed) Siegenthalers Differenzialdiagnose: Innere Krankheiten - vom Symptom zur Diagnose. 2012; Georg Thieme Verlag, Stuttgart 2012: 111-216.

Andere Arbeiten

1. Bosshard PP, Graf N, Knaute DF, Kundig T, Lautenschlager S, Weber R. Response of Treponema pallidum Particle Agglutination Test Titers to Treatment of Syphilis. Clin Infect Dis. 2012. [Epub ahead of print]
2. H. Sax, A. Stewardson, B. Allegranzi, J.M. Boyce, L. Clack, E.L. Larson, D. Pittet. Beyond reasonable doubt: evidence for 'My 5 moments for hand hygiene. The Bone and Joint Journal, eLetter, Aug 6 2012 (<http://www.bjj.boneandjoint.org.uk/content/94-B/4/441.abstract/reply#content-block>)

Dissertationen

1. Meier S. Extended-spectrum β -lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: An increasing challenge for antimicrobial therapy. Dissertation an der Universität Zürich, 2012.
2. Savaria F, Zbinden R, Wüst J, Burnens A, Ledergerber B, Weber R, Kovari H. Antibiotikaresistenzen von E. coli in Urinproben: Prävalenzdaten dreier Laboratorien im Raum Zürich von 1985 bis 2010. Dissertation an der Universität Zürich, 2012.
3. Sonzogni O. The Role of Suppressor of Cytokine Signaling 1 and 3 in Human Cytomegalovirus Replication. Dissertation an der Universität Zürich (MNF), 2012.
4. Zürcher C. Effect of clindamycin and immunoglobulins on Group A Streptococcus virulence factors. Dissertation an der Universität Zürich, 2012.

Masterarbeiten

1. Keller N. Protective effect of interferon alpha in bacterial infections in group a streptococcus. Masterarbeit an der Universität Zürich, (MNF), 2012.
2. Schärer V. Multiresistente Tuberkulose in der Schweiz – Ein Aufarbeitung anhand von zwei Fällen. Masterarbeit an der Universität Zürich, Medizinische Fakultät, 2012.
3. Spring L. Die chronische Hepatitis C Virus (HCV) Infektion bei HIV-koinfizierten Patienten der Schweizerischen HIV Kohortenstudie (SHCS) im Raum Zürich: Prävalenz, Therapieerfolg und Faktoren, welche den Therapieerfolg beeinflussen. Masterarbeit an der Universität Zürich, Medizinische Fakultät, 2012.

